- Home
- CTNT vs GOVX Comparison
CTNT vs GOVX Comparison
Compare CTNT & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNT | GOVX |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.0M |
| IPO Year | 2023 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CTNT | GOVX |
|---|---|---|
| Price | $2.33 | $0.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 13.9M | 799.5K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.74 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,288,536.00 | ★ $2,489,145.00 |
| Revenue This Year | $78.50 | N/A |
| Revenue Next Year | $52.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 182.69 | N/A |
| 52 Week Low | $0.03 | $0.22 |
| 52 Week High | $2,120.00 | $151.70 |
Technical Indicators
Market Signals| Indicator | CTNT | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 20.95 |
| Support Level | $2.28 | N/A |
| Resistance Level | $3.92 | $0.46 |
| Average True Range (ATR) | 0.29 | 0.04 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 6.12 | 0.78 |
Price Performance
Historical ComparisonAbout CTNT Cheetah Net Supply Chain Service Inc.
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.